Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03515538 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
A Phase 2 study, sponsored by EpicentRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT03515538 is a Phase 2 study that has completed, run by EpicentRx. The registered enrollment target is 53 participants.
The verdict
NCT03515538, a Phase 2 study, has completed, sponsored by EpicentRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients in arms 1, 2 and 3 will also receive RRx-001 on different schedules.
Interventions
- RADIATION Radiation Therapy
- DRUG RRx-001
- DRUG Cisplatin for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2018-07-12 |
| Est. Completion | 2020-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03515538
The ClinicalTrials.gov registry entry for NCT03515538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EpicentRx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT03515538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03515538 about?
NCT03515538 is a clinical study titled "Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers". The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy give...
What is the current status of trial NCT03515538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2018-07-12. Estimated completion is 2020-10-08.
What interventions are being tested in trial NCT03515538?
The interventions under investigation include: Radiation Therapy (RADIATION), RRx-001 (DRUG), Cisplatin for injection (DRUG).
Who is sponsoring clinical trial NCT03515538?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.